YAP1 and Alzheimer disease: Reduced TEAD2 levels in 3xTg cortices and Aβ-treated PC12 cells [24], along with reduced expression in the APP/PS1 hippocampus [21] of YAP-TEAD target CDK6 [108], further suggest the involvement of Hippo/YAP-dependent signaling in AD.